umu.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
DNA methylation holds prognostic information in relapsed precursor B-cell acute lymphoblastic leukemia
Umeå universitet, Medicinska fakulteten, Institutionen för medicinsk biovetenskap, Patologi.
Umeå universitet, Medicinska fakulteten, Institutionen för medicinsk biovetenskap, Patologi.
Umeå universitet, Medicinska fakulteten, Institutionen för medicinsk biovetenskap, Patologi.
Vise andre og tillknytning
2018 (engelsk)Inngår i: Clinical Epigenetics, E-ISSN 1868-7083, Vol. 10, artikkel-id 31Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background: Few biological markers are associated with survival after relapse of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). In pediatric T-cell ALL, we have identified promoter-associated methylation alterations that correlate with prognosis. Here, the prognostic relevance of CpG island methylation phenotype (CIMP) classification was investigated in pediatric BCP-ALL patients.

Methods: Six hundred and one BCP-ALL samples from Nordic pediatric patients (age 1-18) were CIMP classified at initial diagnosis and analyzed in relation to clinical data.

Results: Among the 137 patients that later relapsed, patients with a CIMP-profile (n = 42) at initial diagnosis had an inferior overall survival (pOS(5years) 33%) compared to CIMP+ patients (n = 95, pOS(5years) 65%) (p = 0.001), which remained significant in a Cox proportional hazards model including previously defined risk factors.

Conclusion: CIMP classification is a strong candidate for improved risk stratification of relapsed BCP-ALL.

sted, utgiver, år, opplag, sider
BioMed Central, 2018. Vol. 10, artikkel-id 31
Emneord [en]
DNA methylation, BCP-ALL, prognosis, CIMP, relapse, risk stratification
HSV kategori
Identifikatorer
URN: urn:nbn:se:umu:diva-146216DOI: 10.1186/s13148-018-0466-3ISI: 000427080200001PubMedID: 29515676OAI: oai:DiVA.org:umu-146216DiVA, id: diva2:1204518
Tilgjengelig fra: 2018-05-08 Laget: 2018-05-08 Sist oppdatert: 2019-02-20bibliografisk kontrollert
Inngår i avhandling
1. DNA methylation signatures in precursor lymphoid neoplasms: with focus on clinical implications &  the biology behind
Åpne denne publikasjonen i ny fane eller vindu >>DNA methylation signatures in precursor lymphoid neoplasms: with focus on clinical implications &  the biology behind
2019 (engelsk)Doktoravhandling, med artikler (Annet vitenskapelig)
Abstract [en]

Precursor lymphoid neoplasms, namely acute lymphoblastic leukemias (ALL) and lymphoblastic lymphomas (LBL), are characterized by an aggressive proliferation of malignant progenitor B- or T-cells. To improve risk classification at diagnosis, better prognostic and treatment stratifying biomarkers are needed. Altered DNA methylation pattern is a hallmark of neoplastic transformation, and has been employed as a molecular prognostic and predictive marker in various cancers, including hematological malignancies. Our research group previously identified a CpG island methylator phenotype (CIMP) panel that classified pediatric T-ALL patients into prognostic subgroups.

The aim of this thesis was to evaluate distinct DNA methylation signatures in precursor lymphoid neoplasms, and to validate the prognostic value of CIMP classification in separate patient cohorts. Additionally, the biological mechanisms underlying the distinct CIMP methylation signatures in these malignancies were investigated.

The prognostic relevance of CIMP classification was validated in an independent Nordic cohort of pediatric T-ALL patients. Combination of CIMP status with minimal residual disease (MRD) status, could further dissect the high-risk MRD positive T-ALL patients into two CIMP subgroups with significantly distinct outcomes. Furthermore, CIMP classification at diagnosis was shown to predict overall survival in relapsed BCP-ALL patients. CIMP methylation signatures were also identified in T-LBL patients, indicating a broader relevance of CIMP based classification in lymphoid malignancies. Investigating the biology behind CIMP methylation signatures showed the association of CIMP status with the proliferative history of the leukemic cells. A differential transcriptomic analysis revealed a correlation of CIMP subgroups with known T-ALL drivers, as well as with novel genes in T-ALL biology. Finally, we identified distinct DNA methylation patterns and genetic aberrations in T-ALL and T-LBL that might contribute to the different clinical presentation of these two diseases. In conclusion, we validated the prognostic significance of CIMP methylation signature in precursor lymphoid malignancies and identified transcriptomic profiles that associated with the subgroups. DNA methylation is a strong candidate for further risk classification in lymphoid neoplasms and our findings can contribute to the identification of new potential targets for treatment.

sted, utgiver, år, opplag, sider
Umeå: Umeå University, 2019. s. 82
Serie
Umeå University medical dissertations, ISSN 0346-6612 ; 2015
Emneord
Acute Lymphoblastic Leukemia, Lymphoma, T-ALL, BCP-ALL, T-LBL, DNA methylation, CIMP, Prognosis, TAL1, HOX.
HSV kategori
Identifikatorer
urn:nbn:se:umu:diva-156642 (URN)978-91-7855-023-4 (ISBN)
Disputas
2019-03-15, Hörsal Betula, Norrlands universitetssjukhus, 90185, Umeå, 09:00 (engelsk)
Opponent
Veileder
Tilgjengelig fra: 2019-02-22 Laget: 2019-02-20 Sist oppdatert: 2019-03-14bibliografisk kontrollert

Open Access i DiVA

fulltext(1312 kB)63 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 1312 kBChecksum SHA-512
1b08cd0224e4ab6c923f229e784c70e733ff204439e6f357a7a42f4ed45dcc6a49979854095aad0d19dc36aa61d42caf914d1b73f31e8ddd51b9d0446fd61e28
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Borssén, MagnusHaider, ZahraLandfors, MattiasLarsson, PärForestier, ErikHultdin, MagnusDegerman, Sofie

Søk i DiVA

Av forfatter/redaktør
Borssén, MagnusHaider, ZahraLandfors, MattiasLarsson, PärForestier, ErikHultdin, MagnusDegerman, Sofie
Av organisasjonen
I samme tidsskrift
Clinical Epigenetics

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 63 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 415 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf